Clearmind reports early safety data from CMND-100 alcohol disorder trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
July 13, 2026 8:17 AM EDTPrincipal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicines Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder
Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (Clearmind or the Company), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today provides key insights from its June 10 webinar, Inside MEAI, during which the Companys CEO and the leading investigators of the Companys ongoing first-in-human clinical trial of CMND-100 (the Trial),... More
